About VISEN Pharmaceuticals
VISEN Pharmaceuticals is a company based in Shanghai (China) founded in 2018. VISEN Pharmaceuticals has raised $150 million across 1 funding round from investors including Ascendis Pharma, Orbimed and HBM Healthcare Investments. The company has 3 employees as of December 31, 2022. VISEN Pharmaceuticals operates in a competitive market with competitors including Neurocrine, Ironwood Pharma, Crinetics, Zucara Therapeutics and MBX Biosciences, among others.
- Headquarter Shanghai, China
- Employees 3 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Visen
-
Annual Revenue
Not available
-
Net Profit
-$25.44 M (USD)28.35as on Dec 31, 2024
-
EBITDA
-$24.08 M (USD)-29.55as on Dec 31, 2024
-
Total Equity Funding
$150 M (USD)
in 1 rounds
-
Latest Funding Round
$150 M (USD), Series B
Jan 08, 2021
-
Investors
Ascendis Pharma
& 9 more
-
Employee Count
3
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of VISEN Pharmaceuticals
Unlock access to complete
Leadership Team
2 people
Human Resources and Administration
1 people
Sales and Marketing
1 people
Unlock access to complete
Funding Insights of VISEN Pharmaceuticals
VISEN Pharmaceuticals has successfully raised a total of $150M through 1 strategic funding round. The most recent funding activity was a Series B round of $150 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in VISEN Pharmaceuticals
VISEN Pharmaceuticals has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Ascendis Pharma, Orbimed and HBM Healthcare Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Life sciences focused VC firm funding companies in the US and Europe
|
Locked | Locked | Locked | |
|
A venture capital firm focused on life sciences innovation.
|
Locked | Locked | Locked |
Investor details for VISEN Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by VISEN Pharmaceuticals
Investment portfolio details for VISEN Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - VISEN Pharmaceuticals
Detailed financials for VISEN Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Visen Pharmaceuticals Comparisons
Peer comparison for VISEN Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of VISEN Pharmaceuticals
VISEN Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurocrine, Ironwood Pharma, Crinetics, Zucara Therapeutics and MBX Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| Locked | Locked | Locked |
Developer of therapies for the treatment of endocrine-related diseases and cancers
|
|
| Locked | Locked | Locked |
Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes
|
|
| Locked | Locked | Locked |
Drugs for rare endocrine diseases are developed and advanced.
|
|
| Locked | Locked | Locked |
Peptide-targeted radiopharmaceuticals for cancer treatment are developed.
|
Detailed competitors of VISEN Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Visen Pharmaceuticals
Complete news archive for VISEN Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VISEN Pharmaceuticals
VISEN Pharmaceuticals was founded in 2018 and raised its 1st funding round 3 years after it was founded.
VISEN Pharmaceuticals is headquartered in Shanghai, China.
Pony Lu is the current CEO of VISEN Pharmaceuticals.
VISEN Pharmaceuticals is a funded company, having raised a total of $150M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at VISEN Pharmaceuticals is 3.
VISEN Pharmaceuticals was founded in 2018 and is headquartered in Shanghai, China. Operations focus on the biotechnology sector, where therapeutics for endocrine-related diseases are developed through the proprietary TransCon platform for transient conjugation. Key products include TransCon hGH for pediatric growth hormone deficiency, TransCon PTH for hypoparathyroidism, and TransCon CNP for achondroplasia, addressing deficiencies in hormone secretion or gland function.
VISEN Pharmaceuticals's top competitors include Ironwood Pharma, Crinetics and Neurocrine.
VISEN Pharmaceuticals has 10 investors. Key investors include Ascendis Pharma, Orbimed, HBM Healthcare Investments, Sherpa Venture Capital, and Pivotal bioVenture Partners.